ArticleInternational journal of clinical and experimental pathology2019
Diagnostic value of a microRNA signature panel in exosomes for patients with hepatocellular carcinoma.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Silent Messengers: The Role of Extracellular Vesicle-Associated miRNAs in the Non-Invasive Profiling of Hepatocellular Carcinoma.Biomedicines · 2026Review
- miRNAs-Set of Plasmatic Extracellular Vesicles as Novel Biomarkers for Hepatocellular Carcinoma Diagnosis Across Tumor Stage and Etiologies.International journal of molecular sciences · 2025Article
- MicroRNAs as Plasma Biomarkers of Hepatocellular Carcinoma in Patients with Liver Cirrhosis-A Cross-Sectional Study.International journal of molecular sciences · 2024Article
- Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles.Frontiers in molecular biosciences · 2023Review
- The Role of miR-29s in Human Cancers-An Update.Biomedicines · 2022Review
- Small extracellular vesicles and liver diseases: From diagnosis to therapy.World journal of hepatology · 2022Review
- Exosomal microRNA panel as a diagnostic biomarker in patients with hepatocellular carcinoma.Frontiers in cell and developmental biology · 2022Article
- Review
- Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Review
- Review
- The Emerging Role of Exosomal miRNAs as Biomarkers for Early Cancer Detection: A Comprehensive Literature Review.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the fifth most frequently diagnosed cancer worldwide and the second most frequent cause of cancer death. The aim of this study is to investigate the early diagnostic value of a panel of peripheral blood exosomal micro-RNAs (miRNAs) in patients with HCC compared with patients with Hepatitis B virus (HBV) and hepatocirrhosis. PATIENTS AND
methodsBlood samples from 72 patients with HCC, 72 patients with hepatocirrhosis and 72 patients with HBV were obtained at Beijing Friendship Hospital, Capital Medical University. The miRNA expression levels were detected by real-time polymerase chain reaction (RT-PCR). Areas under curve (AUCs) were used to compare diagnostic values of plasmic and exosomal miRNAs.
resultsWe screened plasmic and exosomal solutions of 3 HCC, 3 cirrhosis and 3 HBV patients to perform miRNA microarray analysis. Three distinctly differential microRNAs including miRNA-26a, miRNA-29c, and miRNA-21 were selected to perform further evaluation. First, we found that the expressions of miRNA-26a, miRNA-29c, and miRNA-21 were significantly lower in patients with HCC compared with cirrhotic and HBV group in both exosomes and plasma. Second, we found miRNA-26a, miRNA-29c, and miRNA-21 were significantly down-regulated in HCC tumor tissues compared with normal tissues. Thirdly, we found miRNAs in exosomes had better diagnostic value for patients with HCC compared with plasmic miRNAs among different groups.
conclusionsIn conclusion, we found that the expression of miRNA-26a, miRNA-29c, and miRNA-21 were significantly lower in patients with HCC, and we confirmed miRNA-26a, miRNA-29c, and miRNA-21 could be identified as independent diagnostic biomarkers for patients with HCC.
Indexed as
Identifiers
31933965PMC6947065W3000118821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.